Laura Litwin

DocwireNews

Individuals with no history of smoking who received low-dose computed tomography (LDCT) screening showed no significant sex-based differences in lung cancer diagnoses, stage distribution, or lung cancer–specific deaths, according to results from a recent study performed by a team of researchers from South Korea.
The study, which was published in JAMA Network Open, sought to explore gender-based differences in lung cancer screening outcomes, as well as potential susceptibility to overdiagnosis, among men and women of Asian descent who had no history of smoking.
Due to the rise in lung cancer diagnoses among individuals who have never smoked in East Asia, opportunistic LDCT screening has increased in popularity. However, the study outlined that there is little evidence supporting the need for lung cancer screening within this population.
Furthermore, the researchers explained that “women typically engage more often with medical care and undergo opportunistic screening more frequently,” leading to an increase in overdiagnosis of indolent cancers in women compared with men.
The multicenter study was performed at health checkup centers in South Korea between 2009 and 2021. Eligible participants included patients between 50 and 80 years old who had no history of smoking and received LDCT lung cancer screening, and a total of 21,062 patients were enrolled in the study. The researchers retrospectively analyzed the data from November 2023 to June 2024 and followed up with participants until December 2022.
Of the total participants, 16,133 were women (76.6%) and 4,929 were men (23.4%). A total of 176 patients (139 women [0.9%] and 37 men [0.8%]) were diagnosed with lung cancer after receiving screening.
When broken down further by sex, the data demonstrated that 131 of 139 women (94.3%) were diagnosed with stage 0 to stage 1 lung cancer, compared with 33 of 37 men (89.2%). In addition, the findings showed “no significant sex-based differences in stage or histologic type distribution.”
Among the entire screened cohort of 21,062 patients, LCSD was found in eight women and three men at the mean follow-up point of 83.8 months. The researchers found “no significant association between sex and cumulative hazards &#8220;of lung cancer diagnosis (adjusted hazard ratio [aHR], 0.90 [95% CI, 0.64-1.26] for men vs women) or lung cancer–specific deaths (aHR, 1.06 [95% CI, 0.28-4.00] for men vs women) after conducting a multivariable analysis.
Moreover, the 5-year lung cancer-specific survival rate was found to be 100% for men versus 97.7% for women, among individuals whose cancer was detected via screening, which demonstrated no significant differences between the sexes.
The results illustrated that among Asian patients with no smoking history who received LDCT screening, there were no gender or sex-based disparities in lung cancer diagnosis, stage distribution, or lung cancer–specific deaths. Furthermore, the investigators concluded that “these findings suggest that men and women who have never smoked would experience similar risks of overdiagnosis with little to no benefit when exposed to indiscriminate screening.”
Source: <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829231">JAMA Network Open</a>

Emily Menendez

ctDNA Detection Outperforms Standard Surveillance in Predicting BTC Recurrence

Bile Duct Cancer

Jordana Jampel

AI Screening Accuracy in MASAI Trial Reduced Screen-Reading Time for Mammography

Breast Cancer News

Novel Predictive Models for Assessing T2D Risk After Gastric Surgery Prove Accurate

Diabetes

Latest News

Are There Gender Disparities in Lung Cancer Screening Outcomes Among People Who Have Never Smoked?

Lung Cancer

Among Asian patients with no smoking history who received LDCT screening, there were no gender or sex-based disparities in lung cancer diagnosis, stage distribution, or LCSD.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe